Dolutegravir-based therapy, diet, physical activity and weight gain: a 48-week prospective cohort in South Africa.

ABSTRACT:

Background

People with HIV (PWH) have experienced excess weight gain on tenofovir, lamivudine, and dolutegravir (TLD). The contribution of lifestyle behavior to this weight gain is poorly understood.

Methods

The Population Effectiveness of Dolutegravir Implementation in sub-Saharan Africa (DISCO Study) was a prospective observational cohort study that followed participants in KwaZulu-Natal, South Africa, transitioning to TLD. Our primary outcome of interest was clinically significant weight gain, defined as ≥10% increase from baseline to 48 weeks. Primary exposures of interest were (1) fruit intake (servings/week), (2) vegetable intake (servings/week), (3) fast food intake frequency, (4) fried food intake frequency, (5) sugar-sweetened beverage (SSB) intake frequency, and (6

SUBMITTER: Tien D 

PROVIDER: S-EPMC12924645 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature